Copper tripeptide in venous ulcers
A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers.
Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP, Taylor EL, Robson MC. · Journal of vascular surgery
Study record
- Population
86 evaluable patients completed a venous-ulcer trial; randomized sample size not stated in the abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — study methods and findings- Formulation
0.4% copper-tripeptide cream versus 1% silver sulfadiazine cream and vehicle. Exact peptide identity not established by this abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — study methods and findings- Route
Topical wound application.
Read source · Abstract-level extractionPrimary abstract — study methods and findings- Dose & frequency
0.4% concentration reported; application quantity/frequency unverified. No human or KLOW regimen is inferred.
Inspect extraction gap · Abstract-level extractionPrimary abstract — study methods and findings- Study design
Prospective randomized evaluator-blinded three-arm comparison.
Read source · Abstract-level extractionPrimary abstract — study methods and findings- Duration
Treatment and follow-up duration not available in the abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — study methods and findings- Reported findings
Copper-tripeptide cream did not differ from vehicle in ulcer-size results; silver sulfadiazine performed better.
Read source · Abstract-level extractionPrimary abstract — study methods and findings- Adverse events
Detailed adverse-event counts and ascertainment unavailable in the abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — reporting limit- Monitoring
Detailed safety-monitoring schedule unavailable in the abstract.
Inspect extraction gap · Abstract-level extractionPrimary abstract — reporting limit
What it supports
Copper-tripeptide cream did not differ from vehicle in ulcer-size results; silver sulfadiazine performed better.
What it does not establish
Negative topical comparator evidence retained. Exact peptide identity requires full text before attributing this specifically to GHK-Cu; not systemic or blend evidence. Abstract-level extraction; source gaps are not evidence of safety.
Funding
Not stated in retrieved abstract.
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library